Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Adjuvant Systemic Therapy Trends in 2021

December 9, 2021
By ONCOLOGY Staff
Publication
Article
OncologyONCOLOGY Vol 35, Issue 12
Pages: 784

As always, keep up with the latest issue of ONCOLOGY® to stay up-to-date on the latest practical and timely clinical information necessary to deliver the highest level of patient care.

As our understanding of systemic therapies expands with a greater breadth of research, established agents in the metastatic setting have begun to assert themselves as options in earlier stages of cancer care.

A big breakthrough in this regard came at the end of 2020 when osimertinib (Tagrisso) was approved as an adjuvant therapy for patients with non–small cell lung cancer (NSCLC) whose tumors harbored mutations in EGFR exon 19 deletions or exon 21 L858R. Results of the phase 3 ADAURA trial (NCT02511106) supported the FDA’s decision to grant this standard-of-care agent in the metastatic setting an addition indication for use in patients with stage IB to IIIA disease.

Since then, there have been multiple approvals of established agents for use in patients with early disease across multiple solid tumors malignancies. Both abemaciclib (Verzenio) and pembrolizumab (Keytruda) earned full approval for indications in early breast cancer. The CDK4/6 inhibitor may now be used in combination with endocrine therapy in the adjuvant setting for hormone receptor–positive, HER2-negative, node-positive early breast cancer at high risk of recurrence with a Ki-67 score of 20% or greater. Pembrolizumab is to be used as both a neoadjuvant treatment in combination with chemotherapy, then as a single agent in the adjuvant setting following surgery.

The PD-1 inhibitor nivolumab (Opdivo) earned an indication from the FDA as adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer who have residual pathologic disease and who previously received chemotherapy. In NSCLC, atezolizumab (Tecentriq) may now be used to treat patients with stage II to IIIA NSCLC with PD-L1 expression of 1% or higher following complete resection and platinum-based chemotherapy. And recently, pembrolizumab won another FDA approval for the adjuvant treatment of patients with renal cell carcinoma who are determined to have intermediate- or high-risk disease following nephrectomy or following nephrectomy and resection of metastatic lesions.

Turning the page on a new year, news trends in oncology for 2022 are yet to be determined but are certainly anticipated to be as or even more exciting than what has already occurred in this space. As always, keep up with the latest issue of ONCOLOGY® to stay up-to-date on the latest practical and timely clinical information necessary to deliver the highest level of patient care.

Download Issue PDF
Articles in this issue

A New Horizon in Cancer Care: Liquid Biopsy
A New Horizon in Cancer Care: Liquid Biopsy
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab
The complexity of carcinosarcoma
The complexity of carcinosarcoma
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor
Expert Commentary on the Product Profile of Loncastuximab Tesirine
Expert Commentary on the Product Profile of Loncastuximab Tesirine
Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer
Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer
Adjuvant Systemic Therapy Trends in 2021
Adjuvant Systemic Therapy Trends in 2021
Recent Videos
Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.